Skip to Content
AntioxidantsAntioxidants
  • Review
  • Open Access

16 September 2022

The Impact of Tobacco Cigarettes, Vaping Products and Tobacco Heating Products on Oxidative Stress

,
,
,
and
1
Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia, 97, 95123 Catania, Italy
2
Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Via S. Sofia, 89, 95123 Catania, Italy
3
Department of Clinical and Experimental Medicine, University of Catania, Via S. Sofia, 97, 95123 Catania, Italy
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Oxidative Stress in Respiratory Diseases

Abstract

Cells constantly produce oxidizing species because of their metabolic activity, which is counteracted by the continuous production of antioxidant species to maintain the homeostasis of the redox balance. A deviation from the metabolic steady state leads to a condition of oxidative stress. The source of oxidative species can be endogenous or exogenous. A major exogenous source of these species is tobacco smoking. Oxidative damage can be induced in cells by chemical species contained in smoke through the generation of pro-inflammatory compounds and the modulation of intracellular pro-inflammatory pathways, resulting in a pathological condition. Cessation of smoking reduces the morbidity and mortality associated with cigarette use. Next-generation products (NGPs), as alternatives to combustible cigarettes, such as electronic cigarettes (e-cig) and tobacco heating products (THPs), have been proposed as a harm reduction strategy to reduce the deleterious impacts of cigarette smoking. In this review, we examine the impact of tobacco smoke and MRPs on oxidative stress in different pathologies, including respiratory and cardiovascular diseases and tumors. The impact of tobacco cigarette smoke on oxidative stress signaling in human health is well established, whereas the safety profile of MRPs seems to be higher than tobacco cigarettes, but further, well-conceived, studies are needed to better understand the oxidative effects of these products with long-term exposure.

1. Introduction

The homeostasis of oxidation–reduction reactions is fundamental in biological processes. This biological redox homeostasis is maintained at a stable but non-equilibrium steady state, and different redox potentials are present at different cellular locations [1,2,3,4]. A deviation from the metabolic steady state leads to the concept of oxidative stress. “Oxidative stress” describes an imbalance between oxidants, such as reactive oxygen species (ROS) or reactive nitrogen species (RSN), and antioxidant species, in favor of oxidants [1]. There are two facets of reactive species: (i) physiological levels of oxidants are used for redox signaling and to control sophisticated biological mechanisms (oxidative eustress); (ii) on the other hand, a high concentration of oxidants causes damage to biomolecules and is harmful to cells (oxidative distress) [1,2,5]. ROS/RNS are reactive chemical species with one or more unpaired electrons in their outer orbital, making these molecules very unstable and able to initiate oxidation [5,6]. The sources of ROS/RNS can be endogenous or exogenous. Endogenous sources result from metabolic reactions, such as during mitochondrial electron transport or during inflammation processes, when numerous enzymatic systems are activated (e.g., NADPH oxidase, xanthine oxidase, myeloperoxidase, lipoxygenase, angiotensin II, and nitric oxide synthase) [5,6,7,8] (Figure 1). Meanwhile, the main exogenous sources of free radicals are environmental pollution and tobacco smoking [7].
Figure 1. Endogenous sources of oxidants. Cellular ROS and RNS can be generated from different metabolic reactions, including mitochondrial electron transport and inflammation processes. Under physiological conditions, 0.2–2% of the electrons in the mitochondrial electron transport escape from the transport and interact with oxygen to produce superoxide (O2•−) or hydrogen peroxide (H2O2). Moreover, inflammatory processes contribute to the increase in ROS/RNS by the activation of numerous pro-oxidant enzymatic systems, such as NADPH oxidase (NOX), xanthine oxidase (XO), myeloperoxidase (MPO), and nitric oxide synthase (NOS). However, the presence of antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX), contributes to maintaining the biological redox homeostasis.
Tobacco smoke is a complex mixture of thousands of different chemical species (e.g., ROS/RNS, quinones, aldehydes, ketones, metals), which significantly contributes to enhanced oxidative stress (Figure 2): a single puff of cigarette smoke contains more than 1015 oxidants/free radicals [9,10,11], which exist in gas and tar phases.
Figure 2. Chemical compounds generated by cigarette smoke and next-generation products (NGPs). Tobacco smoke is a complex mixture of thousands of different harmful and potentially harmful chemical species, including toxicants, carcinogens, and organic compounds (left panel). Aerosols generated by NGPs also contain harmful and potentially harmful compounds produced through the thermal decomposition of the solvents, but their quantity is generally lower compared to the ones found in cigarette smoke.
In addition to numerous ROS, epoxides, peroxynitrate, and NO are present in the gas phase, whereas the tar phase contains semiquinone, peroxides, hydroxyl radicals, hydrogen peroxide, and other organic compounds, which are involved in redox cycling with the generation of the superoxide anion [12,13]. Direct or indirect oxidative damage can be induced by these reactive chemical compounds, through the generation of pro-inflammatory compounds (chemokines, cytokines, prostaglandins, leukotrienes, isoprostanes) and the modulation of intracellular pro-inflammatory pathways (MAPK, NF-kB, AP-1, Keapl-Nrf2-ARE) [10,14,15,16]. Consequently, the inhalation of cigarette smoke contributes to the onset, maintenance, and progression of the inflammatory response, resulting in several so-called tobacco-related diseases (respiratory and cardiovascular diseases, tumors, etc.) [10,17,18,19]. Comparisons between tobacco smoke and electronic cigarette (e-cigarette) aerosol showed that the latter released lower levels of toxic compounds (e.g., formaldehyde, acetaldehyde, acrolein, and toluene) and ROS, but non-negligible levels of potential carcinogens, heavy metals, tin, silicate beads, flavoring, and propylene oxide derived from propylene glycol heating (e-cigarette solvent).
Cessation of smoking reduces the morbidity and mortality associated with cigarette use, and improves tobacco-related health consequences [20,21,22]. Therefore, rigorous efforts to control tobacco use, including increased taxation, enhanced educational programs and campaigns, prohibiting smoking in public areas, and the provision of smoking cessation services, have been implemented [21]. Nevertheless, cigarette smoking remains the most important preventable risk factor for morbidity and mortality worldwide, even though a reduction in smoking prevalence was observed in the past after the application of these measures [23]. Lower-risk alternatives to combustible cigarettes have been proposed as a harm reduction strategy to reduce the deleterious impacts of cigarette smoking [24]. This was the focus of the development of next-generation products (NGPs), including e-cigarettes and tobacco-heating products (THPs). E-cigarettes are electrical devices that heat and vaporize a liquid solution, containing propylene glycol (PG) and vegetal glycerol (VG) with or without nicotine, and, in most cases, flavorings.
Meanwhile, THPs generate aerosols containing nicotine by heating a small element, similar to a small cigarette, including a tobacco plug into a hollow acetate tube, a polymer–film filter, a cellulose–acetate mouthpiece filter, and mouth-end papers, generally to referred as a heated tobacco product (HTP) [25], with reduced temperatures (up to 350 °C) that do not reach combustion (about 900 °C) [26].
The exponential growth and use of these products has generated an intensive debate about their public health impact, which has divided the scientific community into two groups: one group believes that NGPs could help smokers to quit cigarette consumption and to reduce its deleterious effects [27,28,29,30]; instead, the other group considers these products as an unsafe alternative to tobacco cigarettes, which could reverse the progress made by tobacco control measurements [31,32,33], bringing young people and future generations to nicotine addiction [34]. In this review, we examine the impact of tobacco smoke and NGPs on oxidative stress in different pathologies, including respiratory and cardiovascular diseases, tumors, and other possible health conditions related to smoking habits.

5. Conclusions

The impact of tobacco cigarette smoke on oxidative stress signaling in respiratory diseases is clear, as with COPD and asthma. The safety profile of NGPs, including electronic cigarettes and tobacco heating products, seems to be higher than that of tobacco cigarettes, but further studies are needed to better understand the toxicological effects of these products with long-term exposure. Despite the relevance of the findings reported in this literature review, some results are of concern regarding experimental and procedural limitations, such as the exposure methods of in vitro studies. Moreover, studies on the safety of the chemical flavorings when vaped are still needed to clarify this important aspect.
The use of a variety in vitro and in vivo models and the non-standardized puffing regimes are important issues for the evaluation of NGPs’ effects, and it is crucial to determine whether and how exposure conditions can be transposed to real-world situations.
To date, the scientific evidence available constitutes a puzzle of information, which, despite the various limitations discussed, already shows a reduced impact of ENDS on oxidative stress compared to cigarette smoking, even if they do not completely eliminate it. This means that the subject remains debated since, however, a negative effect on cellular health is also induced by ENDS. We can therefore state that these devices represent a promising harm reduction tool, but not a harm eradication tool. Above all, we do not yet possess a full understanding of the extent of the harm reduction of ENDS compared to the tobacco cigarette.

Author Contributions

Conceptualization, G.L.V. and M.C.; methodology, R.E.; writing—original draft preparation, R.E., D.C. and R.P.; writing—review and editing, R.E., M.C. and G.L.V.; visualization, R.E.; supervision, M.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sies, H.; Berndt, C.; Jones, D.P. Oxidative Stress. Annu. Rev. Biochem. 2017, 86, 715–748. [Google Scholar] [CrossRef]
  2. Kemp, M.; Go, Y.M.; Jones, D.P. Nonequilibrium thermodynamics of thiol/disulfide redox systems: A perspective on redox systems biology. Free Radic. Biol. Med. 2008, 44, 921–937. [Google Scholar] [CrossRef]
  3. Sacerdoti, D.; Colombrita, C.; Ghattas, M.H.; Ismaeil, E.F.; Scapagnini, G.; Bolognesi, M.; Li Volti, G.; Abraham, N.G. Heme oxygenase-1 transduction in endothelial cells causes downregulation of monocyte chemoattractant protein-1 and of genes involved in inflammation and growth. Cell. Mol. Biol. (Noisy-le-grand) 2005, 51, 363–370. [Google Scholar]
  4. Kushida, T.; LiVolti, G.; Goodman, A.I.; Abraham, N.G. TNF-alpha-mediated cell death is attenuated by retrovirus delivery of human heme oxygenase-1 gene into human microvessel endothelial cells. Transplant. Proc. 2002, 34, 2973–2978. [Google Scholar] [CrossRef]
  5. Mittal, M.; Siddiqui, M.R.; Tran, K.; Reddy, S.P.; Malik, A.B. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 2014, 20, 1126–1167. [Google Scholar] [CrossRef] [PubMed]
  6. Halliwell, B. Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet 1994, 344, 721–724. [Google Scholar] [CrossRef]
  7. Liguori, I.; Russo, G.; Curcio, F.; Bulli, G.; Aran, L.; Della-Morte, D.; Gargiulo, G.; Testa, G.; Cacciatore, F.; Bonaduce, D.; et al. Oxidative stress, aging, and diseases. Clin. Interv. Aging. 2018, 13, 757–772. [Google Scholar] [CrossRef]
  8. Acquaviva, R.; Lanteri, R.; Li Destri, G.; Caltabiano, R.; Vanella, L.; Lanzafame, S.; Di Cataldo, A.; Li Volti, G.; Di Giacomo, C. Beneficial effects of rutin and L-arginine coadministration in a rat model of liver ischemia-reperfusion injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296, G664–G670. [Google Scholar] [CrossRef]
  9. Rahman, I.; Biswas, S.K.; Kode, A. Oxidant and antioxidant balance in the airways and airway diseases. Eur. J. Pharmacol. 2006, 533, 222–239. [Google Scholar] [CrossRef]
  10. Yanbaeva, D.G.; Dentener, M.A.; Creutzberg, E.C.; Wesseling, G.; Wouters, E.F. Systemic effects of smoking. Chest 2007, 131, 1557–1566. [Google Scholar] [CrossRef]
  11. Ientile, R.; Campisi, A.; Raciti, G.; Caccamo, D.; Curro, M.; Cannavo, G.; Li Volti, G.; Macaione, S.; Vanella, A. Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells. J. Neurosci. Res. 2003, 74, 52–59. [Google Scholar] [CrossRef] [PubMed]
  12. Seagrave, J. Oxidative mechanisms in tobacco smoke-induced emphysema. J. Toxicol. Environ. Health A 2000, 61, 69–78. [Google Scholar] [CrossRef] [PubMed]
  13. Tibullo, D.; Barbagallo, I.; Giallongo, C.; Vanella, L.; Conticello, C.; Romano, A.; Saccone, S.; Godos, J.; Di Raimondo, F.; Li Volti, G. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells. Oncotarget 2016, 7, 28868–28880. [Google Scholar] [CrossRef]
  14. Zuo, L.; Otenbaker, N.P.; Rose, B.A.; Salisbury, K.S. Molecular mechanisms of reactive oxygen species-related pulmonary inflammation and asthma. Mol. Immunol. 2013, 56, 57–63. [Google Scholar] [CrossRef]
  15. Colombo, G.; Clerici, M.; Giustarini, D.; Portinaro, N.M.; Aldini, G.; Rossi, R.; Milzani, A.; Dalle-Donne, I. Pathophysiology of tobacco smoke exposure: Recent insights from comparative and redox proteomics. Mass Spectrom. Rev. 2014, 33, 183–218. [Google Scholar] [CrossRef] [PubMed]
  16. Rom, O.; Kaisari, S.; Aizenbud, D.; Reznick, A.Z. Identification of possible cigarette smoke constituents responsible for muscle catabolism. J. Muscle Res. Cell Motil. 2012, 33, 199–208. [Google Scholar] [CrossRef]
  17. Rom, O.; Avezov, K.; Aizenbud, D.; Reznick, A.Z. Cigarette smoking and inflammation revisited. Respir. Physiol. Neurobiol. 2013, 187, 5–10. [Google Scholar] [CrossRef]
  18. Lee, J.; Taneja, V.; Vassallo, R. Cigarette smoking and inflammation: Cellular and molecular mechanisms. J. Dent. Res. 2012, 91, 142–149. [Google Scholar] [CrossRef]
  19. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General; Centers for Disease Control and Prevention (US): Atlanta, GA, USA, 2010. [Google Scholar]
  20. U.S. Public Health Service. 2008 PHS Guideline Update Panel, Liaisons and Staff: Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir. Care 2008, 53, 1217–1222. [Google Scholar]
  21. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017: Monitoring Tobacco Use and Prevention Policies; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
  22. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General; Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2014; Volume 2021. [Google Scholar]
  23. Farsalinos, K. Electronic cigarettes: An aid in smoking cessation, or a new health hazard? Ther. Adv. Respir. Dis. 2018, 12, 1753465817744960. [Google Scholar] [CrossRef]
  24. Fagerstrom, K.O.; Bridgman, K. Tobacco harm reduction: The need for new products that can compete with cigarettes. Addict. Behav. 2014, 39, 507–511. [Google Scholar] [CrossRef] [PubMed]
  25. PMI. Heets and Heatsticks. Available online: https://www.pmi.com/glossary-section/glossary/heets-and-heatsticks (accessed on 5 July 2022).
  26. Kauneliene, V.; Meisutovic-Akhtarieva, M.; Martuzevicius, D. A review of the impacts of tobacco heating system on indoor air quality versus conventional pollution sources. Chemosphere 2018, 206, 568–578. [Google Scholar] [CrossRef] [PubMed]
  27. McNeill, A.; Etter, J.F.; Farsalinos, K.; Hajek, P.; le Houezec, J.; McRobbie, H. A critique of a World Health Organization-commissioned report and associated paper on electronic cigarettes. Addiction 2014, 109, 2128–2134. [Google Scholar] [CrossRef] [PubMed]
  28. Middlekauff, H.R. COUNTERPOINT: Does the Risk of Electronic Cigarettes Exceed Potential Benefits? No. Chest 2015, 148, 582–584. [Google Scholar] [CrossRef]
  29. Etter, J.F. Should electronic cigarettes be as freely available as tobacco? Yes. BMJ 2013, 346, f3845. [Google Scholar] [CrossRef]
  30. Salomone, F.; Li Volti, G.; Vitaglione, P.; Morisco, F.; Fogliano, V.; Zappala, A.; Palmigiano, A.; Garozzo, D.; Caporaso, N.; D’Argenio, G.; et al. Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. Transl. Res. 2014, 163, 593–602. [Google Scholar] [CrossRef] [PubMed]
  31. Schraufnagel, D.E.; Blasi, F.; Drummond, M.B.; Lam, D.C.; Latif, E.; Rosen, M.J.; Sansores, R.; Van Zyl-Smit, R.; Forum of International Respiratory, S. Electronic cigarettes. A position statement of the forum of international respiratory societies. Am. J. Respir. Crit. Care Med. 2014, 190, 611–618. [Google Scholar] [CrossRef]
  32. Chapman, S. Should electronic cigarettes be as freely available as tobacco cigarettes? No. BMJ 2013, 346, f3840. [Google Scholar] [CrossRef]
  33. Avdalovic, M.V.; Murin, S. POINT: Does the Risk of Electronic Cigarettes Exceed Potential Benefits? Yes. Chest 2015, 148, 580–582. [Google Scholar] [CrossRef][Green Version]
  34. Ferkol, T.W.; Farber, H.J.; La Grutta, S.; Leone, F.T.; Marshall, H.M.; Neptune, E.; Pisinger, C.; Vanker, A.; Wisotzky, M.; Zabert, G.E.; et al. Electronic cigarette use in youths: A position statement of the Forum of International Respiratory Societies. Eur. Respir. J. 2018, 51, 1800278. [Google Scholar] [CrossRef]
  35. Crystal, R.G. Oxidants and respiratory tract epithelial injury: Pathogenesis and strategies for therapeutic intervention. Am. J. Med. 1991, 91, 39S–44S. [Google Scholar] [CrossRef]
  36. Holguin, F. Oxidative stress in airway diseases. Ann. Am. Thorac. Soc. 2013, 10, S150–S157. [Google Scholar] [CrossRef] [PubMed]
  37. Kinnula, V.L.; Crapo, J.D.; Raivio, K.O. Generation and disposal of reactive oxygen metabolites in the lung. Lab. Invest. 1995, 73, 3–19. [Google Scholar] [PubMed]
  38. Kirkham, P.; Rahman, I. Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol. Ther. 2006, 111, 476–494. [Google Scholar] [CrossRef]
  39. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007, 87, 245–313. [Google Scholar] [CrossRef]
  40. Reddy, P.H. Mitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant Therapeutics. Pharmaceuticals (Basel) 2011, 4, 429–456. [Google Scholar] [CrossRef]
  41. Kinnula, V.L.; Crapo, J.D. Superoxide dismutases in the lung and human lung diseases. Am. J. Respir. Crit. Care Med. 2003, 167, 1600–1619. [Google Scholar] [CrossRef]
  42. Halliwell, B.; Gutteridge, J.M. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol. 1990, 186, 1–85. [Google Scholar] [CrossRef]
  43. Poli, G.; Leonarduzzi, G.; Biasi, F.; Chiarpotto, E. Oxidative stress and cell signalling. Curr. Med. Chem. 2004, 11, 1163–1182. [Google Scholar] [CrossRef]
  44. Bogdan, C. Nitric oxide synthase in innate and adaptive immunity: An update. Trends Immunol. 2015, 36, 161–178. [Google Scholar] [CrossRef]
  45. Dweik, R.A. Nitric oxide, hypoxia, and superoxide: The good, the bad, and the ugly! Thorax 2005, 60, 265–267. [Google Scholar] [CrossRef] [PubMed][Green Version]
  46. Kirkham, P.A.; Spooner, G.; Ffoulkes-Jones, C.; Calvez, R. Cigarette smoke triggers macrophage adhesion and activation: Role of lipid peroxidation products and scavenger receptor. Free Radic. Biol. Med. 2003, 35, 697–710. [Google Scholar] [CrossRef]
  47. Plaschke, P.P.; Janson, C.; Norrman, E.; Bjornsson, E.; Ellbjar, S.; Jarvholm, B. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. Am. J. Respir. Crit. Care Med. 2000, 162, 920–924. [Google Scholar] [CrossRef]
  48. Rasmussen, F.; Siersted, H.C.; Lambrechtsen, J.; Hansen, H.S.; Hansen, N.C. Impact of airway lability, atopy, and tobacco smoking on the development of asthma-like symptoms in asymptomatic teenagers. Chest 2000, 117, 1330–1335. [Google Scholar] [CrossRef] [PubMed]
  49. Kim, Y.K.; Kim, S.H.; Tak, Y.J.; Jee, Y.K.; Lee, B.J.; Kim, S.H.; Park, H.W.; Jung, J.W.; Bahn, J.W.; Chang, Y.S.; et al. High prevalence of current asthma and active smoking effect among the elderly. Clin. Exp. Allergy 2002, 32, 1706–1712. [Google Scholar] [CrossRef] [PubMed]
  50. Polosa, R.; Russo, C.; Caponnetto, P.; Bertino, G.; Sarva, M.; Antic, T.; Mancuso, S.; Al-Delaimy, W.K. Greater severity of new onset asthma in allergic subjects who smoke: A 10-year longitudinal study. Respir. Res. 2011, 12, 16. [Google Scholar] [CrossRef] [PubMed]
  51. Kleniewska, P.; Pawliczak, R. The participation of oxidative stress in the pathogenesis of bronchial asthma. Biomed Pharm. 2017, 94, 100–108. [Google Scholar] [CrossRef]
  52. Kettle, A.J.; Turner, R.; Gangell, C.L.; Harwood, D.T.; Khalilova, I.S.; Chapman, A.L.; Winterbourn, C.C.; Sly, P.D.; Arest, C.F. Oxidation contributes to low glutathione in the airways of children with cystic fibrosis. Eur. Respir. J. 2014, 44, 122–129. [Google Scholar] [CrossRef]
  53. Ziady, A.G.; Hansen, J. Redox balance in cystic fibrosis. Int. J. Biochem. Cell Biol. 2014, 52, 113–123. [Google Scholar] [CrossRef]
  54. Wood, L.G.; Garg, M.L.; Simpson, J.L.; Mori, T.A.; Croft, K.D.; Wark, P.A.; Gibson, P.G. Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am. J. Respir. Crit. Care Med. 2005, 171, 426–430. [Google Scholar] [CrossRef]
  55. Bargagli, E.; Olivieri, C.; Bennett, D.; Prasse, A.; Muller-Quernheim, J.; Rottoli, P. Oxidative stress in the pathogenesis of diffuse lung diseases: A review. Respir. Med. 2009, 103, 1245–1256. [Google Scholar] [CrossRef] [PubMed]
  56. Faner, R.; Rojas, M.; Macnee, W.; Agusti, A. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012, 186, 306–313. [Google Scholar] [CrossRef] [PubMed]
  57. Fulton, D.J.R.; Li, X.; Bordan, Z.; Haigh, S.; Bentley, A.; Chen, F.; Barman, S.A. Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension. Antioxidants (Basel) 2017, 6, 54. [Google Scholar] [CrossRef] [PubMed]
  58. Page, C.; O’Shaughnessy, B.; Barnes, P. Pathogenesis of COPD and Asthma. Handb. Exp. Pharmacol. 2017, 237, 1–21. [Google Scholar] [CrossRef]
  59. MacNee, W. Pathogenesis of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005, 2, 258–266, discussion 290–251. [Google Scholar] [CrossRef]
  60. Corradi, M.; Pignatti, P.; Manini, P.; Andreoli, R.; Goldoni, M.; Poppa, M.; Moscato, G.; Balbi, B.; Mutti, A. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur. Respir. J. 2004, 24, 1011–1017. [Google Scholar] [CrossRef]
  61. Singh, S.; Verma, S.K.; Kumar, S.; Ahmad, M.K.; Nischal, A.; Singh, S.K.; Dixit, R.K. Evaluation of Oxidative Stress and Antioxidant Status in Chronic Obstructive Pulmonary Disease. Scand. J. Immunol. 2017, 85, 130–137. [Google Scholar] [CrossRef]
  62. Kinnula, V.L.; Ilumets, H.; Myllarniemi, M.; Sovijarvi, A.; Rytila, P. 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur. Respir. J. 2007, 29, 51–55. [Google Scholar] [CrossRef]
  63. Brindicci, C.; Ito, K.; Torre, O.; Barnes, P.J.; Kharitonov, S.A. Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients. Chest 2009, 135, 353–367. [Google Scholar] [CrossRef]
  64. Bernardo, I.; Bozinovski, S.; Vlahos, R. Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities. Pharmacol. Ther. 2015, 155, 60–79. [Google Scholar] [CrossRef]
  65. Vaguliene, N.; Zemaitis, M.; Lavinskiene, S.; Miliauskas, S.; Sakalauskas, R. Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease. BMC Immunol. 2013, 14, 36. [Google Scholar] [CrossRef] [PubMed]
  66. Barnes, P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev. 2004, 56, 515–548. [Google Scholar] [CrossRef] [PubMed]
  67. Liu, X.; Hao, B.; Ma, A.; He, J.; Liu, X.; Chen, J. The Expression of NOX4 in Smooth Muscles of Small Airway Correlates with the Disease Severity of COPD. Biomed. Res. Int. 2016, 2016, 2891810. [Google Scholar] [CrossRef] [PubMed]
  68. Ricciardolo, F.L.; Caramori, G.; Ito, K.; Capelli, A.; Brun, P.; Abatangelo, G.; Papi, A.; Chung, K.F.; Adcock, I.; Barnes, P.J.; et al. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2005, 116, 1028–1035. [Google Scholar] [CrossRef]
  69. Ichinose, M.; Sugiura, H.; Yamagata, S.; Koarai, A.; Shirato, K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am. J. Respir. Crit. Care Med. 2000, 162, 701–706. [Google Scholar] [CrossRef]
  70. Domej, W.; Oettl, K.; Renner, W. Oxidative stress and free radicals in COPD--implications and relevance for treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2014, 9, 1207–1224. [Google Scholar] [CrossRef]
  71. Jiang, Y.; Wang, X.; Hu, D. Mitochondrial alterations during oxidative stress in chronic obstructive pulmonary disease. Int J Chron. Obstruct. Pulmon. Dis. 2017, 12, 1153–1162. [Google Scholar] [CrossRef]
  72. Cantin, A.M. Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. 2016, 13 (Suppl. S2), S150–S155. [Google Scholar] [CrossRef]
  73. Polosa, R.; Knoke, J.D.; Russo, C.; Piccillo, G.; Caponnetto, P.; Sarva, M.; Proietti, L.; Al-Delaimy, W.K. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. J. Allergy Clin. Immunol. 2008, 121, 1428–1434. [Google Scholar] [CrossRef]
  74. Sorrenti, V.; Mazza, F.; Campisi, A.; Vanella, L.; Li Volti, G.; Di Giacomo, C. High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr. Neurovasc. Res. 2006, 3, 49–54. [Google Scholar] [CrossRef]
  75. Lange, P.; Parner, J.; Vestbo, J.; Schnohr, P.; Jensen, G. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998, 339, 1194–1200. [Google Scholar] [CrossRef] [PubMed]
  76. Lee, J.H.; Haselkorn, T.; Borish, L.; Rasouliyan, L.; Chipps, B.E.; Wenzel, S.E. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: Insights from the TENOR study. Chest 2007, 132, 1882–1889. [Google Scholar] [CrossRef] [PubMed]
  77. Westerhof, G.A.; Vollema, E.M.; Weersink, E.J.; Reinartz, S.M.; de Nijs, S.B.; Bel, E.H. Predictors for the development of progressive severity in new-onset adult asthma. J. Allergy Clin. Immunol. 2014, 134, 1051–1056-e1052. [Google Scholar] [CrossRef]
  78. Emma, R.; Bansal, A.T.; Kolmert, J.; Wheelock, C.E.; Dahlen, S.E.; Loza, M.J.; De Meulder, B.; Lefaudeux, D.; Auffray, C.; Dahlen, B.; et al. Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. PLoS ONE 2018, 13, e0203874. [Google Scholar] [CrossRef]
  79. Al Obaidi, A.H.; Al Samarai, A.M. Biochemical markers as a response guide for steroid therapy in asthma. J. Asthma. 2008, 45, 425–428. [Google Scholar] [CrossRef] [PubMed]
  80. Takahashi, K.; Pavlidis, S.; Ng Kee Kwong, F.; Hoda, U.; Rossios, C.; Sun, K.; Loza, M.; Baribaud, F.; Chanez, P.; Fowler, S.J.; et al. Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: An exploratory analysis. Eur. Respir. J. 2018, 51, 1702173. [Google Scholar] [CrossRef]
  81. Carpagnano, G.E.; Lacedonia, D.; Malerba, M.; Palmiotti, G.A.; Cotugno, G.; Carone, M.; Foschino-Barbaro, M.P. Analysis of mitochondrial DNA alteration in new phenotype ACOS. BMC Pulm. Med. 2016, 16, 31. [Google Scholar] [CrossRef]
  82. Lerner, C.A.; Sundar, I.K.; Yao, H.; Gerloff, J.; Ossip, D.J.; McIntosh, S.; Robinson, R.; Rahman, I. Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS ONE 2015, 10, e0116732. [Google Scholar] [CrossRef]
  83. Sussan, T.E.; Gajghate, S.; Thimmulappa, R.K.; Ma, J.; Kim, J.H.; Sudini, K.; Consolini, N.; Cormier, S.A.; Lomnicki, S.; Hasan, F.; et al. Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLoS ONE 2015, 10, e0116861. [Google Scholar] [CrossRef]
  84. CORESTA. CORESTA recommended method no 81. Routine analytical machine for e-cigarette aerosol generation and collection–definitions and standard conditions. 2015. Available online: https://www.coresta.org/sites/default/files/technical_documents/main/CRM_81.pdf (accessed on 5 July 2022).
  85. Shivalingappa, P.C.; Hole, R.; Westphal, C.V.; Vij, N. Airway Exposure to E-Cigarette Vapors Impairs Autophagy and Induces Aggresome Formation. Antioxid. Redox. Signal. 2016, 24, 186–204. [Google Scholar] [CrossRef]
  86. Scheffler, S.; Dieken, H.; Krischenowski, O.; Forster, C.; Branscheid, D.; Aufderheide, M. Evaluation of E-cigarette liquid vapor and mainstream cigarette smoke after direct exposure of primary human bronchial epithelial cells. Int. J. Environ. Res. Public Health 2015, 12, 3915–3925. [Google Scholar] [CrossRef] [PubMed]
  87. ISO/TR 19478-2:2015; ISO and Health Canada Intense Smoking Parameters—Part 2: Examination of Factors Contributing to Variability in the Routine Measurement of TPM, Water and NFDPM Smoke Yields of Cigarettes. ISO: Geneva, Switzerland, 2015.
  88. Taylor, M.; Carr, T.; Oke, O.; Jaunky, T.; Breheny, D.; Lowe, F.; Gaca, M. E-cigarette aerosols induce lower oxidative stress in vitro when compared to tobacco smoke. Toxicol. Mech. Methods 2016, 26, 465–476. [Google Scholar] [CrossRef] [PubMed]
  89. Malinska, D.; Szymanski, J.; Patalas-Krawczyk, P.; Michalska, B.; Wojtala, A.; Prill, M.; Partyka, M.; Drabik, K.; Walczak, J.; Sewer, A.; et al. Assessment of mitochondrial function following short- and long-term exposure of human bronchial epithelial cells to total particulate matter from a candidate modified-risk tobacco product and reference cigarettes. Food Chem. Toxicol. 2018, 115, 1–12. [Google Scholar] [CrossRef]
  90. Moses, E.; Wang, T.; Corbett, S.; Jackson, G.R.; Drizik, E.; Perdomo, C.; Perdomo, C.; Kleerup, E.; Brooks, D.; O’Connor, G.; et al. Molecular Impact of Electronic Cigarette Aerosol Exposure in Human Bronchial Epithelium. Toxicol. Sci. 2017, 155, 248–257. [Google Scholar] [CrossRef]
  91. Jabba, S.V.; Diaz, A.N.; Erythropel, H.C.; Zimmerman, J.B.; Jordt, S.E. Chemical Adducts of Reactive Flavor Aldehydes Formed in E-Cigarette Liquids Are Cytotoxic and Inhibit Mitochondrial Function in Respiratory Epithelial Cells. Nicotine Tob. Res. 2020, 22, S25–S34. [Google Scholar] [CrossRef] [PubMed]
  92. Niemann, B.; Rohrbach, S.; Miller, M.R.; Newby, D.E.; Fuster, V.; Kovacic, J.C. Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series. J. Am. Coll. Cardiol. 2017, 70, 230–251. [Google Scholar] [CrossRef]
  93. Lim, S.S.; Vos, T.; Flaxman, A.D.; Danaei, G.; Shibuya, K.; Adair-Rohani, H.; Amann, M.; Anderson, H.R.; Andrews, K.G.; Aryee, M.; et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2224–2260. [Google Scholar] [CrossRef]
  94. Siti, H.N.; Kamisah, Y.; Kamsiah, J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul. Pharmacol. 2015, 71, 40–56. [Google Scholar] [CrossRef]
  95. Kattoor, A.J.; Pothineni, N.V.K.; Palagiri, D.; Mehta, J.L. Oxidative Stress in Atherosclerosis. Curr. Atheroscler. Rep. 2017, 19, 42. [Google Scholar] [CrossRef]
  96. Forstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2012, 33, 829–837, 837a–837d. [Google Scholar] [CrossRef]
  97. Busse, R.; Luckhoff, A.; Bassenge, E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn Schmiedebergs Arch. Pharmacol. 1987, 336, 566–571. [Google Scholar] [CrossRef] [PubMed]
  98. Alheid, U.; Frolich, J.C.; Forstermann, U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb. Res. 1987, 47, 561–571. [Google Scholar] [CrossRef]
  99. Zeiher, A.M.; Fisslthaler, B.; Schray-Utz, B.; Busse, R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ. Res. 1995, 76, 980–986. [Google Scholar] [CrossRef] [PubMed]
  100. Garg, U.C.; Hassid, A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Investig. 1989, 83, 1774–1777. [Google Scholar] [CrossRef]
  101. Nakaki, T.; Nakayama, M.; Kato, R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur. J. Pharmacol. 1990, 189, 347–353. [Google Scholar] [CrossRef]
  102. Hogan, M.; Cerami, A.; Bucala, R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J. Clin. Investig. 1992, 90, 1110–1115. [Google Scholar] [CrossRef]
  103. Forstermann, U. Oxidative stress in vascular disease: Causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5, 338–349. [Google Scholar] [CrossRef]
  104. Vaziri, N.D.; Rodriguez-Iturbe, B. Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2006, 2, 582–593. [Google Scholar] [CrossRef]
  105. Sydow, K.; Munzel, T. ADMA and oxidative stress. Atheroscler. Suppl. 2003, 4, 41–51. [Google Scholar] [CrossRef]
  106. Forstermann, U.; Munzel, T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 2006, 113, 1708–1714. [Google Scholar] [CrossRef]
  107. Sun, X.; Kumar, S.; Sharma, S.; Aggarwal, S.; Lu, Q.; Gross, C.; Rafikova, O.; Lee, S.G.; Dasarathy, S.; Hou, Y.; et al. Endothelin-1 induces a glycolytic switch in pulmonary arterial endothelial cells via the mitochondrial translocation of endothelial nitric oxide synthase. Am. J. Respir. Cell Mol. Biol. 2014, 50, 1084–1095. [Google Scholar] [CrossRef] [PubMed]
  108. Vanella, L.; Barbagallo, I.; Tibullo, D.; Forte, S.; Zappala, A.; Li Volti, G. The non-canonical functions of the heme oxygenases. Oncotarget 2016, 7, 69075–69086. [Google Scholar] [CrossRef] [PubMed]
  109. Mollnau, H.; Wendt, M.; Szocs, K.; Lassegue, B.; Schulz, E.; Oelze, M.; Li, H.; Bodenschatz, M.; August, M.; Kleschyov, A.L.; et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 2002, 90, E58–E65. [Google Scholar] [CrossRef] [PubMed]
  110. Nickenig, G.; Harrison, D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation 2002, 105, 393–396. [Google Scholar] [CrossRef]
  111. Rahman, M.M.; Laher, I. Structural and functional alteration of blood vessels caused by cigarette smoking: An overview of molecular mechanisms. Curr. Vasc. Pharmacol. 2007, 5, 276–292. [Google Scholar] [CrossRef]
  112. Barua, R.S.; Ambrose, J.A.; Srivastava, S.; DeVoe, M.C.; Eales-Reynolds, L.J. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: An in vitro demonstration in human coronary artery endothelial cells. Circulation 2003, 107, 2342–2347. [Google Scholar] [CrossRef]
  113. Csiszar, A.; Podlutsky, A.; Wolin, M.S.; Losonczy, G.; Pacher, P.; Ungvari, Z. Oxidative stress and accelerated vascular aging: Implications for cigarette smoking. Front. Biosci. Landmark 2009, 14, 3128–3144. [Google Scholar] [CrossRef]
  114. Celermajer, D.S.; Adams, M.R.; Clarkson, P.; Robinson, J.; McCredie, R.; Donald, A.; Deanfield, J.E. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med. 1996, 334, 150–154. [Google Scholar] [CrossRef]
  115. Zeiher, A.M.; Schachinger, V.; Minners, J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995, 92, 1094–1100. [Google Scholar] [CrossRef]
  116. Csordas, A.; Bernhard, D. The biology behind the atherothrombotic effects of cigarette smoke. Nat. Rev. Cardiol. 2013, 10, 219–230. [Google Scholar] [CrossRef]
  117. Raveendran, M.; Wang, J.; Senthil, D.; Wang, J.; Utama, B.; Shen, Y.; Dudley, D.; Zhang, Y.; Wang, X.L. Endogenous nitric oxide activation protects against cigarette smoking induced apoptosis in endothelial cells. FEBS Lett. 2005, 579, 733–740. [Google Scholar] [CrossRef] [PubMed]
  118. Jaimes, E.A.; DeMaster, E.G.; Tian, R.X.; Raij, L. Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1031–1036. [Google Scholar] [CrossRef] [PubMed]
  119. Kayyali, U.S.; Budhiraja, R.; Pennella, C.M.; Cooray, S.; Lanzillo, J.J.; Chalkley, R.; Hassoun, P.M. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol. Appl. Pharmacol. 2003, 188, 59–68. [Google Scholar] [CrossRef]
  120. Talukder, M.A.; Johnson, W.M.; Varadharaj, S.; Lian, J.; Kearns, P.N.; El-Mahdy, M.A.; Liu, X.; Zweier, J.L. Chronic cigarette smoking causes hypertension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice. Am. J. Physiol. Heart Circ. Physiol. 2011, 300, H388–H396. [Google Scholar] [CrossRef]
  121. Lander, H.M.; Milbank, A.J.; Tauras, J.M.; Hajjar, D.P.; Hempstead, B.L.; Schwartz, G.D.; Kraemer, R.T.; Mirza, U.A.; Chait, B.T.; Burk, S.C.; et al. Redox regulation of cell signalling. Nature 1996, 381, 380–381. [Google Scholar] [CrossRef]
  122. Flohe, L.; Brigelius-Flohe, R.; Saliou, C.; Traber, M.G.; Packer, L. Redox regulation of NF-kappa B activation. Free Radic. Biol. Med. 1997, 22, 1115–1126. [Google Scholar] [CrossRef]
  123. Van den Berg, R.; Haenen, G.R.; van den Berg, H.; Bast, A. Nuclear factor-kappaB activation is higher in peripheral blood mononuclear cells of male smokers. Environ. Toxicol. Pharmacol. 2001, 9, 147–151. [Google Scholar] [CrossRef]
  124. Orosz, Z.; Csiszar, A.; Labinskyy, N.; Smith, K.; Kaminski, P.M.; Ferdinandy, P.; Wolin, M.S.; Rivera, A.; Ungvari, Z. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: Role of NAD(P)H oxidase activation. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H130–H139. [Google Scholar] [CrossRef]
  125. Csiszar, A.; Smith, K.E.; Koller, A.; Kaley, G.; Edwards, J.G.; Ungvari, Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: Role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation 2005, 111, 2364–2372. [Google Scholar] [CrossRef]
  126. Wissler, R.W. New insights into the pathogenesis of atherosclerosis as revealed by PDAY. Pathobiological Determinants of Atherosclerosis in Youth. Atherosclerosis 1994, 108, S3–S20. [Google Scholar] [CrossRef]
  127. Miyaura, S.; Eguchi, H.; Johnston, J.M. Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid, platelet-activating factor. Circ. Res. 1992, 70, 341–347. [Google Scholar] [CrossRef] [PubMed]
  128. Imaizumi, T.; Satoh, K.; Yoshida, H.; Kawamura, Y.; Hiramoto, M.; Takamatsu, S. Effect of cigarette smoking on the levels of platelet-activating factor-like lipid(s) in plasma lipoproteins. Atherosclerosis 1991, 87, 47–55. [Google Scholar] [CrossRef]
  129. Perlstein, T.S.; Lee, R.T. Smoking, metalloproteinases, and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 250–256. [Google Scholar] [CrossRef]
  130. Newby, A.C. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc. Med. 2007, 17, 253–258. [Google Scholar] [CrossRef] [PubMed]
  131. Shah, P.K.; Falk, E.; Badimon, J.J.; Fernandez-Ortiz, A.; Mailhac, A.; Villareal-Levy, G.; Fallon, J.T.; Regnstrom, J.; Fuster, V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995, 92, 1565–1569. [Google Scholar]
  132. Kangavari, S.; Matetzky, S.; Shah, P.K.; Yano, J.; Chyu, K.Y.; Fishbein, M.C.; Cercek, B. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J. Cardiovasc. Pharmacol. Ther. 2004, 9, 291–298. [Google Scholar] [CrossRef]
  133. Huang, B.; Svensson, P.; Arnlov, J.; Sundstrom, J.; Lind, L.; Ingelsson, E. Effects of cigarette smoking on cardiovascular-related protein profiles in two community-based cohort studies. Atherosclerosis 2016, 254, 52–58. [Google Scholar] [CrossRef]
  134. Teasdale, J.E.; Newby, A.C.; Timpson, N.J.; Munafo, M.R.; White, S.J. Cigarette smoke but not electronic cigarette aerosol activates a stress response in human coronary artery endothelial cells in culture. Drug. Alcohol. Depend. 2016, 163, 256–260. [Google Scholar] [CrossRef]
  135. Anderson, C.; Majeste, A.; Hanus, J.; Wang, S. E-Cigarette Aerosol Exposure Induces Reactive Oxygen Species, DNA Damage, and Cell Death in Vascular Endothelial Cells. Toxicol. Sci. 2016, 154, 332–340. [Google Scholar] [CrossRef]
  136. Carnevale, R.; Sciarretta, S.; Violi, F.; Nocella, C.; Loffredo, L.; Perri, L.; Peruzzi, M.; Marullo, A.G.; De Falco, E.; Chimenti, I.; et al. Acute Impact of Tobacco vs Electronic Cigarette Smoking on Oxidative Stress and Vascular Function. Chest 2016, 150, 606–612. [Google Scholar] [CrossRef]
  137. Chaumont, M.; de Becker, B.; Zaher, W.; Culie, A.; Deprez, G.; Melot, C.; Reye, F.; Van Antwerpen, P.; Delporte, C.; Debbas, N.; et al. Differential Effects of E-Cigarette on Microvascular Endothelial Function, Arterial Stiffness and Oxidative Stress: A Randomized Crossover Trial. Sci. Rep. 2018, 8, 10378. [Google Scholar] [CrossRef] [PubMed]
  138. Ikonomidis, I.; Vlastos, D.; Kourea, K.; Kostelli, G.; Varoudi, M.; Pavlidis, G.; Efentakis, P.; Triantafyllidi, H.; Parissis, J.; Andreadou, I.; et al. Electronic Cigarette Smoking Increases Arterial Stiffness and Oxidative Stress to a Lesser Extent Than a Single Conventional Cigarette: An Acute and Chronic Study. Circulation 2018, 137, 303–306. [Google Scholar] [CrossRef] [PubMed]
  139. Espinoza-Derout, J.; Hasan, K.M.; Shao, X.M.; Jordan, M.C.; Sims, C.; Lee, D.L.; Sinha, S.; Simmons, Z.; Mtume, N.; Liu, Y.; et al. Chronic intermittent electronic cigarette exposure induces cardiac dysfunction and atherosclerosis in apolipoprotein-E knockout mice. Am. J. Physiol. Heart Circ. Physiol. 2019, 317, H445–H459. [Google Scholar] [CrossRef]
  140. Farsalinos, K.E.; Kistler, K.A.; Pennington, A.; Spyrou, A.; Kouretas, D.; Gillman, G. Aldehyde levels in e-cigarette aerosol: Findings from a replication study and from use of a new-generation device. Food Chem. Toxicol. 2018, 111, 64–70. [Google Scholar] [CrossRef] [PubMed]
  141. Kuntic, M.; Oelze, M.; Steven, S.; Kroller-Schon, S.; Stamm, P.; Kalinovic, S.; Frenis, K.; Vujacic-Mirski, K.; Bayo Jimenez, M.T.; Kvandova, M.; et al. Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: Evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2). Eur. Heart J. 2020, 41, 2472–2483. [Google Scholar] [CrossRef]
  142. Lee, W.H.; Ong, S.G.; Zhou, Y.; Tian, L.; Bae, H.R.; Baker, N.; Whitlatch, A.; Mohammadi, L.; Guo, H.; Nadeau, K.C.; et al. Modeling Cardiovascular Risks of E-Cigarettes With Human-Induced Pluripotent Stem Cell-Derived Endothelial Cells. J. Am. Coll. Cardiol. 2019, 73, 2722–2737. [Google Scholar] [CrossRef]
  143. Benz, C.C.; Yau, C. Ageing, oxidative stress and cancer: Paradigms in parallax. Nat. Rev. Cancer 2008, 8, 875–879. [Google Scholar] [CrossRef]
  144. Oberley, L.W. Free radicals and diabetes. Free Radic. Biol. Med. 1988, 5, 113–124. [Google Scholar] [CrossRef]
  145. Okamoto, K.; Toyokuni, S.; Uchida, K.; Ogawa, O.; Takenewa, J.; Kakehi, Y.; Kinoshita, H.; Hattori-Nakakuki, Y.; Hiai, H.; Yoshida, O. Formation of 8-hydroxy-2’-deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. Int. J. Cancer 1994, 58, 825–829. [Google Scholar] [CrossRef]
  146. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug. Discov. 2009, 8, 579–591. [Google Scholar] [CrossRef]
  147. Boonstra, J.; Post, J.A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004, 337, 1–13. [Google Scholar] [CrossRef] [PubMed]
  148. Schafer, F.Q.; Buettner, G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 2001, 30, 1191–1212. [Google Scholar] [CrossRef]
  149. Martindale, J.L.; Holbrook, N.J. Cellular response to oxidative stress: Signaling for suicide and survival. J. Cell. Physiol. 2002, 192, 1–15. [Google Scholar] [CrossRef] [PubMed]
  150. Ranjan, P.; Anathy, V.; Burch, P.M.; Weirather, K.; Lambeth, J.D.; Heintz, N.H. Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. Antioxid. Redox. Signal. 2006, 8, 1447–1459. [Google Scholar] [CrossRef] [PubMed]
  151. Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug. Discov. 2013, 12, 931–947. [Google Scholar] [CrossRef]
  152. Hecht, S.S. Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol. 2002, 3, 461–469. [Google Scholar] [CrossRef]
  153. Liu, X.; Chen, Z. The pathophysiological role of mitochondrial oxidative stress in lung diseases. J. Transl. Med. 2017, 15, 207. [Google Scholar] [CrossRef]
  154. Xu, D.; Rovira, I.I.; Finkel, T. Oxidants painting the cysteine chapel: Redox regulation of PTPs. Dev. Cell 2002, 2, 251–252. [Google Scholar] [CrossRef]
  155. Leslie, N.R.; Bennett, D.; Lindsay, Y.E.; Stewart, H.; Gray, A.; Downes, C.P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003, 22, 5501–5510. [Google Scholar] [CrossRef]
  156. WHO. Tobacco or health: A global status report. 1997. Available online: https://apps.who.int/iris/handle/10665/41922 (accessed on 5 July 2022).
  157. Levin, M.L.; Goldstein, H.; Gerhardt, P.R. Cancer and tobacco smoking; a preliminary report. J. Am. Med. Assoc. 1950, 143, 336–338. [Google Scholar] [CrossRef]
  158. Doll, R.; Hill, A.B. Smoking and carcinoma of the lung; preliminary report. Br. Med. J. 1950, 2, 739–748. [Google Scholar] [CrossRef]
  159. International Agency for Research on Cancer (IARC). Tobacco Smoking; 92 832 1238 X; WHO: Geneva, Switzerland, 1986. [Google Scholar]
  160. International Agency for Research on Cancer (IARC). Tobacco smoke and involuntary smoking; WHO: Geneva, Switzerland, 2004. [Google Scholar]
  161. Gandini, S.; Botteri, E.; Iodice, S.; Boniol, M.; Lowenfels, A.B.; Maisonneuve, P.; Boyle, P. Tobacco smoking and cancer: A meta-analysis. Int. J. Cancer 2008, 122, 155–164. [Google Scholar] [CrossRef] [PubMed]
  162. Leanderson, P.; Tagesson, C. Cigarette smoke-induced DNA-damage: Role of hydroquinone and catechol in the formation of the oxidative DNA-adduct, 8-hydroxydeoxyguanosine. Chem. Biol. Interact. 1990, 75, 71–81. [Google Scholar] [CrossRef]
  163. Asami, S.; Manabe, H.; Miyake, J.; Tsurudome, Y.; Hirano, T.; Yamaguchi, R.; Itoh, H.; Kasai, H. Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis 1997, 18, 1763–1766. [Google Scholar] [CrossRef] [PubMed]
  164. Huang, M.F.; Lin, W.L.; Ma, Y.C. A study of reactive oxygen species in mainstream of cigarette. Indoor Air 2005, 15, 135–140. [Google Scholar] [CrossRef]
  165. Valavanidis, A.; Vlachogianni, T.; Fiotakis, K. Tobacco smoke: Involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int. J. Environ. Res. Public Health 2009, 6, 445–462. [Google Scholar] [CrossRef]
  166. Lala, P.K.; Chakraborty, C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001, 2, 149–156. [Google Scholar] [CrossRef]
  167. Lowe, F.J.; Luettich, K.; Gregg, E.O. Lung cancer biomarkers for the assessment of modified risk tobacco products: An oxidative stress perspective. Biomarkers 2013, 18, 183–195. [Google Scholar] [CrossRef]
  168. Ichinose, T.; Yajima, Y.; Nagashima, M.; Takenoshita, S.; Nagamachi, Y.; Sagai, M. Lung carcinogenesis and formation of 8-hydroxy-deoxyguanosine in mice by diesel exhaust particles. Carcinogenesis 1997, 18, 185–192. [Google Scholar] [CrossRef]
  169. Kim, J.Y.; Mukherjee, S.; Ngo, L.C.; Christiani, D.C. Urinary 8-hydroxy-2’-deoxyguanosine as a biomarker of oxidative DNA damage in workers exposed to fine particulates. Environ. Health Perspect 2004, 112, 666–671. [Google Scholar] [CrossRef]
  170. Cao, C.; Lai, T.; Li, M.; Zhou, H.; Lv, D.; Deng, Z.; Ying, S.; Chen, Z.; Li, W.; Shen, H. Smoking-promoted oxidative DNA damage response is highly correlated to lung carcinogenesis. Oncotarget 2016, 7, 18919–18926. [Google Scholar] [CrossRef] [PubMed]
  171. Advani, J.; Subbannayya, Y.; Patel, K.; Khan, A.A.; Patil, A.H.; Jain, A.P.; Solanki, H.S.; Radhakrishnan, A.; Pinto, S.M.; Sahasrabuddhe, N.A.; et al. Long-Term Cigarette Smoke Exposure and Changes in MiRNA Expression and Proteome in Non-Small-Cell Lung Cancer. OMICS 2017, 21, 390–403. [Google Scholar] [CrossRef] [PubMed]
  172. Goniewicz, M.L.; Knysak, J.; Gawron, M.; Kosmider, L.; Sobczak, A.; Kurek, J.; Prokopowicz, A.; Jablonska-Czapla, M.; Rosik-Dulewska, C.; Havel, C.; et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob. Control 2014, 23, 133–139. [Google Scholar] [CrossRef] [PubMed]
  173. Takahashi, Y.; Kanemaru, Y.; Fukushima, T.; Eguchi, K.; Yoshida, S.; Miller-Holt, J.; Jones, I. Chemical analysis and in vitro toxicological evaluation of aerosol from a novel tobacco vapor product: A comparison with cigarette smoke. Regul. Toxicol. Pharmacol. 2018, 92, 94–103. [Google Scholar] [CrossRef]
  174. Schaller, J.P.; Keller, D.; Poget, L.; Pratte, P.; Kaelin, E.; McHugh, D.; Cudazzo, G.; Smart, D.; Tricker, A.R.; Gautier, L.; et al. Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol. Regul. Toxicol. Pharmacol. 2016, 81 (Suppl. S2), S27–S47. [Google Scholar] [CrossRef]
  175. Jaccard, G.; Tafin Djoko, D.; Moennikes, O.; Jeannet, C.; Kondylis, A.; Belushkin, M. Comparative assessment of HPHC yields in the Tobacco Heating System THS2.2 and commercial cigarettes. Regul. Toxicol. Pharmacol. 2017, 90, 1–8. [Google Scholar] [CrossRef]
  176. Saffari, A.; Daher, N.; Ruprecht, A.; De Marco, C.; Pozzi, P.; Boffi, R.; Hamad, S.H.; Shafer, M.M.; Schauer, J.J.; Westerdahl, D.; et al. Particulate metals and organic compounds from electronic and tobacco-containing cigarettes: Comparison of emission rates and secondhand exposure. Environ. Sci. Process Impacts 2014, 16, 2259–2267. [Google Scholar] [CrossRef]
  177. Ganapathy, V.; Manyanga, J.; Brame, L.; McGuire, D.; Sadhasivam, B.; Floyd, E.; Rubenstein, D.A.; Ramachandran, I.; Wagener, T.; Queimado, L. Electronic cigarette aerosols suppress cellular antioxidant defenses and induce significant oxidative DNA damage. PLoS ONE 2017, 12, e0177780. [Google Scholar] [CrossRef]
  178. Breheny, D.; Adamson, J.; Azzopardi, D.; Baxter, A.; Bishop, E.; Carr, T.; Crooks, I.; Hewitt, K.; Jaunky, T.; Larard, S.; et al. A novel hybrid tobacco product that delivers a tobacco flavour note with vapour aerosol (Part 2): In vitro biological assessment and comparison with different tobacco-heating products. Food Chem. Toxicol. 2017, 106, 533–546. [Google Scholar] [CrossRef]
  179. Tang, M.S.; Wu, X.R.; Lee, H.W.; Xia, Y.; Deng, F.M.; Moreira, A.L.; Chen, L.C.; Huang, W.C.; Lepor, H. Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. Proc. Natl. Acad. Sci. USA 2019, 116, 21727–21731. [Google Scholar] [CrossRef]
  180. Canistro, D.; Vivarelli, F.; Cirillo, S.; Babot Marquillas, C.; Buschini, A.; Lazzaretti, M.; Marchi, L.; Cardenia, V.; Rodriguez-Estrada, M.T.; Lodovici, M.; et al. E-cigarettes induce toxicological effects that can raise the cancer risk. Sci. Rep. 2017, 7, 2028. [Google Scholar] [CrossRef] [PubMed]
  181. Cirillo, S.; Vivarelli, F.; Turrini, E.; Fimognari, C.; Burattini, S.; Falcieri, E.; Rocchi, M.B.L.; Cardenia, V.; Rodriguez-Estrada, M.T.; Paolini, M.; et al. The customizable e-cigarette resistance influences toxicological outcomes: Lung degeneration, inflammation and oxidative stress-induced in a rat model. Toxicol. Sci. 2019, 172, 132–145. [Google Scholar] [CrossRef] [PubMed]
  182. Song, M.A.; Freudenheim, J.L.; Brasky, T.M.; Mathe, E.A.; McElroy, J.P.; Nickerson, Q.A.; Reisinger, S.A.; Smiraglia, D.J.; Weng, D.Y.; Ying, K.L.; et al. Biomarkers of Exposure and Effect in the Lungs of Smokers, Nonsmokers, and Electronic Cigarette Users. Cancer Epidemiol. Biomark. Prev. 2020, 29, 443–451. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.